A specialty pharmaceutical company focused on acquiring, developing, and marketing off‑patent prescription medicines, often targeting niche or legacy therapies with limited competition. The firm expanded rapidly through debt‑funded acquisitions, including the purchase of Amdipharm Mercury, creating ...
No congressional trades have been disclosed for Concordia Therapeutics, Inc (CXRX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.